tiprankstipranks
Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright
PremiumThe FlyCartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright
19d ago
Cartesian Therapeutics Reports Promising Phase 2b Trial Results
Premium
Company Announcements
Cartesian Therapeutics Reports Promising Phase 2b Trial Results
20d ago
Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia
Premium
The Fly
Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia
20d ago
Cartesian Therapeutics price target lowered to $41 from $45 at H.C. Wainwright
PremiumThe FlyCartesian Therapeutics price target lowered to $41 from $45 at H.C. Wainwright
1M ago
Cartesian Therapeutics reports Q3 EPS ($1.13) , consensus (79c)
Premium
The Fly
Cartesian Therapeutics reports Q3 EPS ($1.13) , consensus (79c)
2M ago
Cartesian announces Phase 2b trial of Descartes-08 achieved primary endpoint
Premium
The Fly
Cartesian announces Phase 2b trial of Descartes-08 achieved primary endpoint
2M ago
Cartesian announces first patient dosed in Phase 1 trial of Descartes-15
PremiumThe FlyCartesian announces first patient dosed in Phase 1 trial of Descartes-15
4M ago
Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright
Premium
The Fly
Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright
5M ago
Cartesian Therapeutics Engages Investors at Conferences
Premium
Company Announcements
Cartesian Therapeutics Engages Investors at Conferences
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100